/PRNewswire/ The Mark Foundation for Cancer Research announced 16 outstanding projects in its latest class of ASPIRE awards, granting more than $5 million.
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments.
Clinical studies reveal extended survival in diffuse midline glioma patients receiving ONC201 treatment; research also explains the underlying mechanism of the drug’s success. For the first time, a potential drug candidate has been identified by researchers that show promise in improving outcomes f
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. The compound nearly doubled survival.